imiglitazar
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
6
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT00759720)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
PPARA agonist
Development discontinued after Ph3 in 2005 due to abnormalities in liver enzyme tests (http://www.firstwordpharma.com/node/218757#axzz3OLRFCbFS3).
PPARG agonist
Development discontinued after Ph3 in 2005 due to abnormalities in liver enzyme tests (http://www.firstwordpharma.com/node/218757#axzz3OLRFCbFS3).
Chemistry & pharmacology
Loading structure…
SMILES
Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1- Mol. weight
- 470.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL592054 ↗
Also known as
- (e)-4-(4-((5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy)benzyloxyimino)-4-phenylbutyric acid
- imiglitazar
- imiglitazar
- imiglitazar
- tak-559
- tak-559
- tak-559
- tak-559
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00762684 | Phase 3 | Nov 1, 2004 | Takeda |
| NCT00762957 | Phase 3 | Nov 1, 2004 | Takeda |
| NCT00759720 | Phase 3 | Nov 1, 2003 | Takeda |
| NCT00762112 | Phase 3 | Nov 1, 2003 | Takeda |
| NCT00762190 | Phase 3 | Nov 1, 2003 | Takeda |
| NCT00763022 | Phase 3 | Nov 1, 2003 | Takeda |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 6 | 6 | 1 | 2003 |
1 organizations
Page 1 / 1